By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

  • Home
  • >
  • Latest Headlines
  • >
  • FDA Rejects PTC’s New Drug Application for Translarna as a Nonsense Mutation DMD Treatment – Muscular Dystrophy News

FDA Rejects PTC’s New Drug Application for Translarna as a Nonsense Mutation DMD Treatment – Muscular Dystrophy News

Friday, 26 February, 2016

FDA Rejects PTC’s New Drug Application for Translarna as a Nonsense Mutation DMD Treatment – Muscular Dystrophy News

Ataluren is a small-molecule protein restoration therapy compound in clinical development for the treatment of Duchenne muscular dystrophy (DMD) caused by a nonsense mutation (nmDMD), cystic fibrosis caused by a nonsense mutation (nmCF), and other ...

Read More

Source:FDA Rejects PTC's New Drug Application for Translarna as a Nonsense Mutation DMD Treatment - Muscular Dystrophy News

Categories :
  • Latest Headlines
  • Muscular Dystrophy
  • Uncategorized
Socials :

Recent posts

Ability Today to your inbox.

By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.

Ability Today to your inbox.

By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.

Our Awards and Partners

Copyright © 2022 All rights reserved